- Home
- QCRH vs CRVS Comparison
QCRH vs CRVS Comparison
Compare QCRH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QCRH | CRVS |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | QCRH | CRVS |
|---|---|---|
| Price | $92.40 | $15.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $98.25 | $30.17 |
| AVG Volume (30 Days) | 85.1K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | 11.62 | ★ 48.04 |
| EPS | ★ 7.49 | N/A |
| Revenue | ★ $165,999,610.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $12.18 | ★ N/A |
| Revenue Growth | ★ 20.72 | N/A |
| 52 Week Low | $63.96 | $3.17 |
| 52 Week High | $96.00 | $26.95 |
Technical Indicators
Market Signals| Indicator | QCRH | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 50.72 |
| Support Level | $80.87 | $14.38 |
| Resistance Level | $94.42 | $18.73 |
| Average True Range (ATR) | 2.34 | 1.18 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 76.41 | 26.38 |
Price Performance
Historical ComparisonAbout QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.